Author

Beno Huglin

Observed institutions: Ifakara Health Institute, National Institute for Medical Research

OpenAlex ID: A5118825202

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial

2025 · Norbert Heinrich, Norbert Heinrich, et al. · The Lancet Infectious Diseases · 20

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

2025 · Simon E Koele, Krista Stoycheva, et al. · Journal of Antimicrobial Chemotherapy · 5

Comparison of VPM1002 with BCG in the prevention of tuberculosis in newborn infants: a multicentre, double-blind, randomised, phase 3, non-inferiority trial

2026 · Videlis Nduba, Matsontso Mathebula, et al. · The Lancet Infectious Diseases

Works count: 3

Citation count: 25

H-index: 2

I10-index: 1